Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Clinical trial NCT02296918 · COMPLETED
Trial details
- NCT number
- NCT02296918
- Sponsor
- Acerta Pharma BV
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-22
- Primary completion
- 2021-08-20
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.